These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 32222885

  • 1. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
    Seth S, Zanwar S, Vu L, Kapoor P.
    Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
    [Abstract] [Full Text] [Related]

  • 2. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
    Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O.
    Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience.
    Alfano G, Fontana F, Colaci E, Messerotti A, Bettelli F, Potenza L, Luppi M, Cappelli G.
    Transplantation; 2017 Nov; 101(11):e337-e342. PubMed ID: 28731904
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
    Landgren O.
    Hematology Am Soc Hematol Educ Program; 2021 Dec 10; 2021(1):662-672. PubMed ID: 34889381
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E, Rognvaldsson S, Thorsteinsdottir S, Einarsson Long T, Reed ER, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Sveinsdottir SV, Sigurdsson F, Thordardottir AR, Palsson R, Indridason OS, Jonsson A, Gislason GK, Olafsson A, Sigurdsson J, Steingrimsdottir H, Hultcrantz M, Durie BGM, Harding S, Landgren O, Aspelund T, Love TJ, Kristinsson SY.
    Ann Intern Med; 2024 Apr 10; 177(4):449-457. PubMed ID: 38560901
    [Abstract] [Full Text] [Related]

  • 13. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA.
    Eur J Haematol Suppl; 1989 Apr 10; 51():70-5. PubMed ID: 2516809
    [Abstract] [Full Text] [Related]

  • 14. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T, Callander N.
    J Natl Compr Canc Netw; 2020 Dec 01; 18(12):1720-1729. PubMed ID: 33347744
    [Abstract] [Full Text] [Related]

  • 15. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G.
    Leukemia; 2020 Dec 01; 34(12):3111-3125. PubMed ID: 33046818
    [Abstract] [Full Text] [Related]

  • 16. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
    Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV.
    JCI Insight; 2019 Apr 23; 5(11):. PubMed ID: 31013254
    [Abstract] [Full Text] [Related]

  • 17. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA, Rajkumar SV.
    Oncology (Williston Park); 2011 Jun 23; 25(7):578-86. PubMed ID: 21888255
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
    Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC.
    Oncology (Williston Park); 2011 Jun 23; 25(7):594, 596. PubMed ID: 21888257
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L, Fernández de Larrea C, Elena M, Cibeira MT, Tovar N, Aróstegui JI, Pedrosa F, Rosiñol L, Filella X, Yagüe J, Bladé J.
    Clin Lymphoma Myeloma Leuk; 2016 Jun 23; 16(6):e71-7. PubMed ID: 27013181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.